Daiichi Sankyo-Merck’s ‘guided-missile’ cancer drug meets main goal in late-stage trial
The trial, involving 586 patients, tested the drug against chemotherapy in patients with non-small cell lung cancer (NSCLC) who had a specific gene mutation leading to abnormal cell growth.